(Q38097749)

28 August 2017

title

Statins and autoimmunity (English)

1 reference

28 August 2017

author

Gisele Zandman-Goddard

series ordinal

2

object named as

Gisele Zandman-Goddard

1 reference

28 August 2017

Saakshi Khattri

1

1 reference

28 August 2017

publication date

1 July 2013

1 reference

28 August 2017

1 reference

28 August 2017

volume

56

1 reference

28 August 2017

issue

2-3

1 reference

28 August 2017

page(s)

348-357

1 reference

https://scigraph.springernature.com/pub.10.1007/s12026-013-8409-8

28 August 2017

exact match

0 references

cites work

Regulation of the mevalonate pathway

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8409-8

Antiinflammatory and immunomodulatory properties of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8409-8

The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8409-8

Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8409-8

Effect of pravastatin on outcomes after cardiac transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8409-8

Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8409-8

Statins as immunomodulators in systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8409-8

Immunomodulatory effects of statins and autoimmune rheumatic diseases: novel intracellular mechanism involved

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8409-8

Statin therapy and autoimmune disease: from protein prenylation to immunomodulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8409-8

Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8409-8

Simvastatin inhibits the MHC class II pathway of antigen presentation by impairing Ras superfamily GTPases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8409-8

Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8409-8

The pathogenesis of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8409-8

Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8409-8

Anti-inflammatory and immunomodulating properties of statins. An additional tool for the therapeutic approach of systemic autoimmune diseases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8409-8

Non-lipid-related effects of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8409-8

NF-kappaB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8409-8

Role of cytokines in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8409-8

Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8409-8

PPAR agonists amplify iNOS expression while inhibiting NF-kappaB: implications for mesangial cell activation by cytokines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8409-8

Isoprenoids as mediators of the biological effects of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8409-8

Pleiotropic effects of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8409-8

A novel anti-inflammatory role for simvastatin in inflammatory arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8409-8

Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8409-8

Persistence with statins and onset of rheumatoid arthritis: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8409-8

Atorvastatin upregulates regulatory T cells and reduces clinical disease activity in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8409-8

Therapy with statins in patients with refractory rheumatic diseases: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8409-8

Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8409-8

Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8409-8

Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8409-8

Statins for the treatment of antiphospholipid syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8409-8

Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8409-8

Grades of recommendation for antithrombotic agents: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8409-8

Management of refractory anti-phospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8409-8

A randomized trial of rosuvastatin in the prevention of venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8409-8

Atorvastatin inhibits autoreactive B cell activation and delays lupus development in New Zealand black/white F1 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8409-8

Effect of combining ACE inhibitor and statin in lupus-prone mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8409-8

Simvastatin treatment ameliorates autoimmune disease associated with accelerated atherosclerosis in a murine lupus model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8409-8

Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: a randomized placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8409-8

The role of atorvastatin in regulating the immune response leading to vascular damage in a model of Kawasaki disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8409-8

Effects of HMG-CoA reductase inhibitors on continuous post-inflammatory vascular remodeling late after Kawasaki disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8409-8

Statin therapy might be beneficial for patients with ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8409-8

Protective effect of pravastatin on vascular endothelium in patients with systemic sclerosis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8409-8

Atherosclerosis and systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8409-8

Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8409-8

Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8409-8

Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8409-8

Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8409-8

C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8409-8

Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8409-8

Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8409-8

Pathogenesis and therapies of immune-mediated myopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8409-8

Baseline levels of c-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis : A ten-year followup study of a primary care-based inception cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8409-8

Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial

21 January 2018

1 reference

12 December 2020

Effects of rosuvastatin on vascular biomarkers and carotid atherosclerosis in lupus: a randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers

1 reference

12 December 2020

High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis

1 reference

12 December 2020

Effect of atorvastatin on inflammation and modification of vascular risk factors in rheumatoid arthritis

1 reference

12 December 2020

Inhibition of systemic sclerosis dermal fibroblast type I collagen production and gene expression by simvastatin

1 reference

12 December 2020

Bilateral, simultaneous rupture of the quadriceps tendon associated with simvastatin

1 reference

12 December 2020

Mortality trends in rheumatoid arthritis: the role of rheumatoid factor

1 reference

12 December 2020

Kawasaki Disease With Particular Emphasis on Arterial Lesions

1 reference

12 December 2020

Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies

1 reference

12 December 2020

Effects of pravastatin in murine collagen-induced arthritis

1 reference

12 December 2020

Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis

1 reference

12 December 2020

A pravastatin dose-escalation study in systemic lupus erythematosus

1 reference

12 December 2020

Small GTP-binding proteins

1 reference

12 December 2020

The value of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: do they imply new risk factors?

1 reference

12 December 2020

Mortality in rheumatoid arthritis: 2008 update.

1 reference

12 December 2020

10.1007/S12026-013-8409-8

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

1026110325

0 references

1 reference